Breast Cancer Breakthroughs: The Importance of ESR1 mutations in metastatic breast cancer

Former Komen grantee Dr. Aditya Bardia explains how metastatic estrogen receptor-positive breast cancers can develop mutations in the estrogen receptor gene, or ESR1. These mutations typically arise after treatment with aromatase inhibitors, which eliminate estrogen from the body. The breast cancer develops ESR1 mutations so that it is no longer dependent on estrogen for growth. Komen Scholar Dr. Donald McDonnell explains how these mutations are different from inherited gene mutations like mutations in the BRCA1 and BRCA2 genes. Dr. Bardia also explains how ESR1 mutations are detected.
Kelsey Hampton, PhD, is Senior Manager, Mission Communications at Susan G. Komen
Dr. Aditya Bardia is a medical oncologist at Massachusetts General Hospital
Dr. Donald McDonnell is a research scientist at Duke University

Sign up for reminders about future episodes of Breast Cancer Breakthroughs here: https://www.komen.org/about-komen/our...
Link to Survey: https://susangkomen.iad1.qualtrics.co...
Clinical Trial Finder: https://www.breastcancertrials.org/BC...

Videos:
Breast Cancer Breakthroughs Episode 7: Brining Treatments to Life:    • Breast Cancer Breakthroughs Episode 7: Bri...  
Under the Microscope: Mutations:    • Mutations and Breast Cancer  
Under the Microscope: Estrogen Receptor:    • Estrogen Receptor: Unlocking breast cancer...  

Resources:
Metastatic Breast Cancer: https://www.komen.org/breast-cancer/m...
Hormone Receptor Status: https://www.komen.org/breast-cancer/d...
Hormone therapy for metastatic breast cancer: https://www.komen.org/breast-cancer/m...
Monitoring metastatic breast cancer: https://www.komen.org/breast-cancer/m...
Emerging areas in diagnosis: https://www.komen.org/breast-cancer/d...
Emerging areas in metastatic breast cancer treatment: https://www.komen.org/breast-cancer/m...
EMERALD Trial (Active, not recruiting): https://www.clinicaltrials.gov/study/...